医学
结直肠癌
背景(考古学)
临床试验
禁忌症
外科
阶段(地层学)
癌症
疾病
辅助治疗
放射治疗
普通外科
化疗
内科学
病理
古生物学
替代医学
生物
作者
Alex Benson,Michael A. Choti,Ariel Cohen,James H. Doroshow,Charles Fuchs,Krystyna Kiel,E. W. Martin,Cornelius J. McGinn,Nicholas J. Petrelli,James Posey,John M. Skibber,Alan P. Venook,Timothy J. Yeatman
出处
期刊:PubMed
日期:2000-11-01
卷期号:14 (11A): 203-12
被引量:13
摘要
The NCCN Colorectal Cancer Guidelines panel believes that a multidisciplinary approach is necessary for the management of the patient with colorectal cancer. The panel endorses the concept that treatment of patients in a clinical trial has priority over standard or accepted therapy. The recommended surgical procedure for resectable colon cancer is an en bloc resection; laparoscopic surgery should be done only in the context of a clinical trial. For patients with stage III disease, 5-FU-based adjuvant therapy is recommended. A patient who has metastatic disease in the liver or lung should be considered for surgical resection if he or she is a candidate for surgery and if surgery can extend survival. Surgery should be followed by adjuvant chemotherapy. The panel advocates a conservative post-treatment surveillance program for colon and rectal carcinoma patients. Serial CEA determinations are appropriate if the patient is a candidate for aggressive surgical resection, should recurrence be detected. Abdominal and pelvic CT scans should be utilized only when there are clinical indications of possible recurrence. Patients whose disease progresses during 5-FU-based therapy should be treated with irinotecan or encouraged to participate in a phase I or phase II clinical trial.
科研通智能强力驱动
Strongly Powered by AbleSci AI